EPISODE · Sep 5, 2022 · 11 MIN
S7 Ep27: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer
from OncLive® On Air · host OncLive® On Air
Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety data from the DESTINY-Breast04 trial, and how these findings pave the way for further progress across cancer therapy.
Embed this episode
NOW PLAYING
S7 Ep27: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer
0:00
11:55
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of OncLive® On Air?
This episode is 11 minutes long.
When was this OncLive® On Air episode published?
This episode was published on September 5, 2022.
Can I download this OncLive® On Air episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!